The University of Texas
MD Anderson Cancer Center

Office of Alumni Relations

Spring Alumni Social
Honoring our Distinguished Alumnus
Kishor M. Wasan , RPh., PhD
Co-Founder & Co-Director, Neglected Global Diseases Initiative
Distingished University Scholar and Adjunct Professor
Faculty of Medicine
University of British Columbia

Thuersday March 27th – 5:30-8:30 p.m.
Saint Arnold Brewing Company
2000 Lyons Avenue
Houston, TX 77020

Space is limited. RSVP in the portal by
March 25, 2025.
Hors d’oeures &beverages will be served.
Must be 21 years or older to attend.

Please join us for our 2025 Spring Social. Go to the Events menu in the portal and use the REGISTER button to RSVP by March 25, 2025. If you are not registered in the alumni portal, you can create your profile here.

NGDI UBC hosted a wonderful workshop on March 11th 2025 in beautiful Vancouver BC, on the UBC Campus to discuss a potential National Global Health Access and Equity Initiative to be led by Canadian Universities.

Thank you to the wonderful speakers and sponsors of the event, Medicines Patent Pool, Doctors without Borders Canada and UAEM.

Please see the link below for the recording of our workshop:
https://lnkd.in/gpAPEcwh
Passcode: j.5c?v9*

Vancouver, Canada - February 25, 2025 - EluciDx Canada Ltd. (EluciDx) and the University of British Columbia (UBC) have signed a licensing agreement for oral amphotericin B, an innovative therapy originally developed by Drs. Kishor Wasan and Ellen Wasan. This breakthrough treatment holds immense potential to expand therapeutic options for life-threatening systemic fungal infections, a growing global health concern.

As the first Canadian university to establish global access principles, UBC has incorporated provisions in the agreement to ensure accessibility in developing countries which EluciDx is committed to realizing. This is particularly critical in regions where HIV/AIDS co-morbidities contribute to high mortality rates and access to the injectable form of amphotericin B is severely limited. EluciDx plans to work closely with the Neglected Global Disease Initiative at UBC (NGDI-UBC) to develop and commercialize oral amphotericin B for low-resource settings, including cutaneous and visceral Leishmaniasis.

EluciDx intends to spin off this asset into an independent company to facilitate capital-raising efforts while efficiently establishing global partnerships for development and manufacturing. EluciDx will employ a dual-track development strategy, aiming to develop first-in-class anti-fungal indications for high-income markets to ensure commercial viability and long-term sustainability of the asset while partnering with NGDI-UBC and African partners to develop its low- and middle-income environment indications in parallel.

"This strategy will allow the dedication of resources to see the development of oral amphotericin B through to registration, reimbursement and beyond - an achievement that has eluded multiple attempts over the past decades," said Dr. James Kim, CEO of EluciDx. Dr. Kishor Wasan, Adjunct Professor and Co-Founder of NGDI-UBC added, "We are committed to delivering this much-needed treatment to patients worldwide, ensuring both access and sustainability."

EluciDx is dedicated to improving outcomes in healthcare through pharmaceuticals, medical devices, in vitro diagnostics and nutraceuticals. Through business strategy and development consulting for startups and mature healthcare companies and also through its own R&D by collaborating with universities and research institutions around the world, EluciDx is committed to developing innovations into sustainable, commercially viable products within global medical practice, regulatory and reimbursement frameworks. For more information, visit the company website at www.elucidx.ca.

Neglected global diseases, such as leishmaniasis, dengue fever and others designated by the World Health Organization (WHO), disproportionately affect the poorest of the global population. NGDI at UBC creates a network to bring together groups interested in making a positive impact and enabling sustained scholarly activity and education in this area. To learn more about NGDI UBC visit our website at: www.ngdi.ubc.ca

James Kim
CEO
contact@elucidx.ca
EluciDx Canada Ltd.

Dr. Kishor M. Wasan
Co-Founder
Kishor.Wasan@ubc.ca
NGDI-UBC

Dundee, United Kingdom - January 15, 2025 - Med eTech Innovation, a leading innovator in medical technology, is pleased to announce the appointment of Professor Kishor Wasan as our new Chief Scientific Officer (CSO). Professor Kishor Wasan brings over 30 years of experience in the field of drug delivery systems for neglected global diseases and will be instrumental in driving the company's research and development initiatives.

Professor Wasan is currently Adjunct Professor & Distinguished University Scholar, Department of Urologic Sciences, Faculty of Medicine at University of British Columbia (UBC), and Co-Founder & Co- Director, Neglected Global Diseases Initiative at UBC. He is the co-inventor of a novel oral amphotericin B formulation to treat leishmaniasis and systemic fungal infections that is cost- effective, safe, and tropically stable. His work has been recognised by several awards, and he is a member of USRA (Lifetime), Canadian Academy of Health Sciences (Fellow) and the Royal Society of Medicine (Fellow). He brings skills in lipid-based drug delivery and pharmaceutical sciences to his new role, particularly regarding bioequivalence studies, GMP and licensing. He will oversee the company's scientific strategy, lead cutting-edge research projects, and collaborate with industry partners to advance Med eTech Innovation's mission of transforming healthcare through technology and process improvement, providing true bench to bedside solutions.

Professor Wasan has further shown his commitment to Med eTech by joining the Board as a Director.

Founded in 2018, Med eTech Innovation Ltd. provides clinical research from drug discovery, drug development onto human early phase through to Late Phase and post-marketing clinical solutions for pharmaceutical, medical device, and nutraceutical companies.

The company is committed to supporting global health access and equity by undertaking clinical trials for neglected diseases in low and middle-income countries (LMICs).

Med eTech Innovation leverages the latest software and business processes for our clinical trial management, ensuring efficiency, accuracy, and compliance with the highest standards.

For more information, please contact: Media Liaison, Med eTech Innovation, press@medetech.org.